The Company intends to commercialize a novel class of drugs that focus on a new treatment approach the Company calls HDL Therapy, which is based upon its understanding of HDL function. Through HDL Therapy, the Company intends to exploit the beneficial properties of HDL in cardiovascular and metabolic diseases with a portfolio of product candidates. Revenues reflect the development stage of the Company's products.
Net loss reflects the costs of developing new products and preferred stock conversion cost.
K Jean-Louis Dasseux, P.h. Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Data and information is provided for informational purposes only, and is not intended for trading purposes.